Facility Design and Operation: A Primer - NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation. - BioPharm International

ADVERTISEMENT

Facility Design and Operation: A Primer
NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation.

BioPharm International
Volume 26, Issue 2, pp. 46-51


Michael Lacey
In this sixth part of a series of primers with training experts from the National Institute for Bioprocessing Research and Training (NIBRT), Plant Manager Michael Lacey discusses the basics of biopharmaceutical facility design and operation. NIBRT provides training, educational, and research solutions for the international bioprocessing industry in state-of-the-art facilities. Located in South Dublin, it is based on an innovative collaboration between University College Dublin, Trinity College Dublin, Dublin City University, and the Institute of Technology Sligo. NIBRT opened a 6500-square-meters facility in June 2011 on a university campus in South Dublin City. The facility holds offices and training rooms, a pilot production plant, and research laboratories with supporting utilities, and offers a wide range of theoretical as well as hands-on training in all aspects of bioprocessing. The facility also has high-end research capability and process development and improvement capability. Lacey is responsible for facility, equipment maintenance, and support services to the plant's core business of bioprocessing, training, and research.

FACILITY PLANNING

BioPharm: What do biopharmaceutical companies just starting out need to keep in mind in terms of planning a new facility's location and construction?

Lacey: There are many factors to consider in terms of choosing location, but some are key. First, the reality is that finance and commercial aspects are major considerations. The second category I would look at is the infrastructural side and the existence of support services. Finally, for me perhaps, the most important factor to consider is the people who run the factory. People are the most important asset a company has.

To expand on those three categories, let's look briefly at the financial and commercial side of things. Corporations are interested in corporation taxes, local taxes, and charges that they will pay in a particular location. They will be looking at their transfer pricing policy. They may have a treasury strategy. They may set up their financial headquarters in a particular location alongside their manufacturing base.

Companies will surely look at the availability of granted training support, and they will be very interested in their cost base; that is, the cost of labor, salaries, wages, transport, and shipping. Very importantly in the European context, companies will be interested in access to markets in certain countries, particularly European Union countries.

Looking at the infrastructural and support services side of things, manufactured product must be brought to the market. Therefore, effective distribution, including storage and freight transport by road, rail, air, and sea, are very important. With regard to a specific location, a company may prefer to set up where there is already a cluster of similar clients with similar requirements. If such a cluster exists, there is likely to be support services available such as laboratory services, maintenance services, project management, regulatory expertise, etc. as well as educational and research support from nearby institutes and colleges.

The third category, people, is based on who will operate and manage the plant. It is crucial to have a strong pool of talented people who are well educated, experienced, and flexible. Those people should also have continuing access to training and education.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here